- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.03. | Following FDA cuts, Trump nominee Makary vows 'independent' staff review | ||
| 06.03. | Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting | ||
| 06.03. | Federal judge extends block on Trump plan to limit NIH payouts | ||
| 06.03. | The top 3 impacts of Trump's health data purge | ||
| 06.03. | Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy | ||
| 06.03. | Tris to ask for approval of dual-acting pain drug | ||
| 05.03. | Jazz expands in oncology with $935M deal for Chimerix | ||
| 05.03. | Bayer braces for 'difficult' year before turnaround pays dividends | ||
| 04.03. | Sofinnova secures €1.2B for new biotech investments | ||
| 04.03. | Neumora bids farewell to R&D head; Biohaven's 'one step forward, one step back' data | ||
| 04.03. | Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda | ||
| 03.03. | Biotech startup pulls in $187M to make 'multi-payload' ADCs | ||
| 03.03. | AbbVie gets into obesity with $350M deal for once-weekly shot | ||
| 03.03. | Protagonist says Takeda-partnered drug succeeds in rare blood cancer | ||
| 28.02. | Leqembi, after delay, gets back on track toward EU approval | ||
| 28.02. | BridgeBio oncology spinout to go public in blank-check merger | ||
| 28.02. | Praxis hits trial setback; Bristol Myers lays off staff in New Jersey | ||
| 27.02. | FDA meeting on flu vaccine composition is canceled | ||
| 27.02. | Vertex ends gene editing research pact with Verve | ||
| 26.02. | Lilly CEO wields manufacturing plans to push pharma-friendly policies | ||
| 26.02. | AstraZeneca's next breast cancer drug; Madrigal's accelerating MASH launch | ||
| 26.02. | Lilly expands US manufacturing build-out with $50B target | ||
| 26.02. | Eikon raises $351M in one of the year's largest biotech venture rounds | ||
| 25.02. | Drug compounders sue FDA over declaration ending Wegovy shortage | ||
| 25.02. | Regeneron gene therapy helps deaf children hear in small study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
